Thermage (monopolar RF) skin tightening: 2026 evidence

Monopolar radiofrequency (MRF), most widely known by the brand name Thermage, has been a workhorse non-invasive option for mild-to-moderate facial laxity for over two decades. The technology delivers volumetric heating to the dermis and subcutaneous tissue through a capacitive-coupled tip, triggering immediate collagen contraction and a slower neocollagenesis response over months. The current platform (Thermage FLX) uses AccuREP impedance feedback to adjust energy delivery to the patient's tissue impedance — a refinement intended to deliver more uniform heating and a more tolerable treatment experience compared with earlier generations.

Mechanism

A monopolar radiofrequency device generates an oscillating electric field between the tip electrode and a return pad on the patient's body. As current flows through tissue, resistive heating raises the temperature of the deep dermis and underlying subcutaneous tissue to approximately 60–75°C at the treatment focus. This thermal load:

• Causes immediate contraction of existing collagen triple helices.
• Triggers a controlled wound-healing response in fibroblasts.
• Drives neocollagenesis (type I and III collagen) and elastin remodeling over the following 3 to 6 months [3].

The latest device generation incorporates real-time impedance measurement (AccuREP) to adjust pulse parameters automatically to each shot, intended to standardize energy delivery across patients with different tissue properties.

Expected timeline

The clinical literature describes a two-phase response:

• Day 0: modest immediate skin contraction visible at treatment, attributable to collagen denaturation.
• Day 30: measurable improvement in laxity grading begins to appear on standardized scales [2].
• Day 90: more visible lift and contour refinement as neocollagenesis matures.
• Day 180: the primary endpoint in most randomized trials; outcomes assessed here are reasonably durable [2].

Patients should be counseled that the meaningful change unfolds over 3 to 6 months, not in the days immediately after a session.

Comparative evidence with MFU-V

For a deeper review of microfocused ultrasound, see our companion article on MFU-V (Ultherapy) skin tightening.

The most informative comparison between monopolar radiofrequency and microfocused ultrasound is a randomized, split-face, evaluator-blind clinical trial that enrolled 20 subjects with mild-to-moderate facial laxity [2]. Each subject received MFU-V on one side of the face and monopolar radiofrequency on the other at a single session, and was followed for six months.

Key findings:

• Both modalities produced statistically significant improvements in the Fasil Face and Neck Laxity Rating scale at day 30, day 90, and day 180.
• The Global Aesthetic Improvement Scale (GAIS) showed comparable subject-reported improvement on both treated sides.
• No statistically significant difference was found between MRF and MFU-V on standardized investigator measures of laxity.
• No statistically significant difference in patient satisfaction or in adverse event rates.

This 20-person trial found no statistically significant difference between the studied treatments; selection also depends on anatomy, settings, risks and operator experience. The trial does not establish general efficacy equivalence. A combined or sequenced approach is also used in clinical practice for patients with both laxity and dermal-quality concerns [2].

Recent device evidence

A 2025 prospective randomized controlled trial compared a novel monopolar RF platform (YOUMAGIC) with the Thermage CPT reference device for the lower face [1]. Forty subjects were randomized 1:1 and followed for six months with Antera 3D photographic assessment of nasolabial fold depression volume. Both arms produced statistically significant reductions in fold depression at 1, 3, and 6 months versus baseline, with no statistically significant difference between arms and no serious adverse events. This non-inferiority data is useful for context, though sample sizes in this class of trial remain modest.

Adverse events and limitations

Across published trials and post-market surveys, the adverse-event profile of contemporary monopolar radiofrequency is generally favorable when treatment is performed by trained operators with appropriately calibrated parameters [1][2][3]:

• Procedural discomfort: the most consistently reported issue; mitigated by topical anesthesia, intra-procedure cryogen cooling, and parameter titration. Newer platforms with vibration tips and impedance feedback report improved tolerability.
• Erythema and edema: typically resolves within hours to days after the procedure.
• Bruising: infrequent.
• Rare adverse events: subcutaneous fat atrophy, burns, post-inflammatory pigment changes (particularly in darker Fitzpatrick skin types), and very rare temporary sensory disturbances. These risks scale with energy parameters and operator technique.

A Korean dermatologist practice survey (n = 82) found 78.8% of respondents reported high satisfaction with monopolar radiofrequency outcomes, and that practice patterns coalesced around 900 shots for facial tightening in patients aged 35 to 65 [3]. This is an indicator of clinician satisfaction in a high-experience market, not a substitute for prospective trial endpoints. Shot count also matters when comparing quotes in Seoul: alongside this survey, Gangnam clinics such as Delight Dermatology publish indicative Thermage FLX price ranges for 300-, 600- and 900-REP tips.

Limitations worth acknowledging:

• Substantial laxity (Glogau IV / severe submental redundancy) is unlikely to be adequately addressed by monopolar radiofrequency alone; surgical options should be discussed.
• Significant facial volume loss is not the primary indication; biostimulator or filler therapy is a separate consideration.
• Outcomes vary with skin type, baseline laxity, and operator parameter selection. Marketing assertions of consistent transformative outcomes are not supported by the controlled-trial evidence base.

Patient selection

Reasonable candidates for monopolar radiofrequency include:

• Patients with mild-to-moderate facial or neck laxity.
• Patients seeking non-invasive maintenance rather than a surgical-equivalent change.
• Patients across Fitzpatrick I–VI when parameters are titrated appropriately.

Cautions or contraindications often cited in clinical practice include:

• Active local infection, severe acne, or recent ablative resurfacing in the treatment area.
• Pacemakers, implanted cardioverter-defibrillators, or other implanted electronics (because the device delivers radiofrequency current through tissue).
• Pregnancy (data limited).
• History of keloid or hypertrophic scarring at facial sites (relative caution).
• Patients with unrealistic outcome expectations — addressed during informed consent rather than at the device.

How MRF fits into a broader plan

Energy-based tightening is one tool in a broader aesthetic plan. Patients with combined laxity and volume loss are often best served by a sequenced approach — for example, monopolar radiofrequency or MFU-V for laxity, biostimulators (such as poly-L-lactic acid or polynucleotide-based products) for dermal quality, and judicious filler use for contour [2]. The order and timing of these interventions are individualized and should be discussed in consultation.

Bottom line

Monopolar radiofrequency is a non-invasive option for mild-to-moderate facial laxity. A 20-person randomized comparison found no statistically significant difference from MFU-V; selection also depends on anatomy, settings, risks and operator experience [2]. Patients should expect a gradual onset over 3 to 6 months, transient post-procedural discomfort, and individualized outcomes rather than an immediate or universal response.